| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leslie Citrome, Constance B Shope, Karen A Nolan, Pal Czobor, Jan Volavk. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. International clinical psychopharmacology. vol 22. issue 6. 2008-01-14. PMID:17917554. |
the objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia. |
2008-01-14 |
2023-08-12 |
Not clear |
| Lesley J Scott, Sohita Dhillo. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatric drugs. vol 9. issue 5. 2008-01-11. PMID:17927305. |
the clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. |
2008-01-11 |
2023-08-12 |
Not clear |
| Lesley J Scott, Sohita Dhillo. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatric drugs. vol 9. issue 5. 2008-01-11. PMID:17927305. |
in the us, risperidone is also approved for the treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years, for the treatment of schizophrenia in adolescents aged 13-17 years and, as monotherapy, for the short-term treatment of acute manic and mixed episodes associated with bipolar i disorder in children and adolescents aged 10-17 years. |
2008-01-11 |
2023-08-12 |
Not clear |
| Arif Khan, Kelly Schwartz, Chelsea Stern, Nick Redding, Russell L Kolts, Walter A Brown, Donald S Robinso. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. The Journal of clinical psychiatry. vol 68. issue 12. 2008-01-10. PMID:18162012. |
given the concern that mortality rates may be increased in geriatric patients exposed to atypical antipsychotic agents, we assessed mortality rates for adult patients with schizophrenia assigned to an investigational antipsychotic (olanzapine, quetiapine, risperidone, or ziprasidone), a control antipsychotic (haloperidol or chlorpromazine), or placebo in preapproval clinical development programs to assess relative risk with atypical antipsychotics as compared to typical antipsychotics or placebo. |
2008-01-10 |
2023-08-12 |
Not clear |
| B Grayson, N F Idris, J C Neil. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural brain research. vol 184. issue 1. 2008-01-09. PMID:17675172. |
clozapine and risperidone but not haloperidol showed efficacy to reverse the deficit induced by sub-chronic pcp suggesting that this test may have some validity for assessing efficacy for improvement of cognitive deficit symptoms of schizophrenia. |
2008-01-09 |
2023-08-12 |
rat |
| Gahan J Pandina, Carla M Canuso, Eriene Youssef, Mary Kujawa, Ramy Mahmou. Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Human psychopharmacology. vol 22. issue 5. 2008-01-08. PMID:17599334. |
limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. |
2008-01-08 |
2023-08-12 |
Not clear |
| T De Marinis, P T Saleem, P Glue, W J Arnoldussen, R Teijeiro, A Lex, M A Latif, R Medor. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. vol 40. issue 6. 2008-01-08. PMID:18030649. |
switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. |
2008-01-08 |
2023-08-12 |
Not clear |
| Nicholas A Keks, Michael Ingham, Akbar Khan, Keith Karche. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. The British journal of psychiatry : the journal of mental science. vol 191. 2008-01-07. PMID:17666497. |
long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. |
2008-01-07 |
2023-08-12 |
Not clear |
| Georges Gharabawi, Cynthia Bossie, Ibrahim Turkoz, Mary Kujawa, Ramy Mahmoud, George Simpso. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. The Journal of nervous and mental disease. vol 195. issue 12. 2008-01-07. PMID:18091190. |
the impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. |
2008-01-07 |
2023-08-12 |
Not clear |
| Georges Gharabawi, Cynthia Bossie, Ibrahim Turkoz, Mary Kujawa, Ramy Mahmoud, George Simpso. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. The Journal of nervous and mental disease. vol 195. issue 12. 2008-01-07. PMID:18091190. |
this post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. |
2008-01-07 |
2023-08-12 |
Not clear |
| R Kaddurah-Daouk, J McEvoy, R A Baillie, D Lee, J K Yao, P M Doraiswamy, K R R Krishna. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular psychiatry. vol 12. issue 10. 2008-01-04. PMID:17440431. |
lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n=20), risperidone (n=14) or aripiprazole (n=16). |
2008-01-04 |
2023-08-12 |
Not clear |
| Wolfgang Gaebel, Mathias Riesbeck, Wolfgang Wölwer, Ansgar Klimke, Matthias Eickhoff, Martina von Wilmsdorff, Maria C Jockers-Scherübl, Kai-Uwe Kühn, Matthias Lemke, Andreas Bechdolf, Stefan Bender, Detlef Degner, Ralf Schlösser, Lutz G Schmidt, Andrea Schmitt, Markus Jäger, Gerd Buchkremer, Peter Falkai, Stefan Klingberg, Wolfgang Köpcke, Wolfgang Maier, Heinz Häfner, Christian Ohmann, Hans J Salize, Frank Schneider, Hans-Jürgen Mölle. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry. vol 68. issue 11. 2008-01-03. PMID:18052570. |
maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the german research network on schizophrenia. |
2008-01-03 |
2023-08-12 |
Not clear |
| Wolfgang Gaebel, Mathias Riesbeck, Wolfgang Wölwer, Ansgar Klimke, Matthias Eickhoff, Martina von Wilmsdorff, Maria C Jockers-Scherübl, Kai-Uwe Kühn, Matthias Lemke, Andreas Bechdolf, Stefan Bender, Detlef Degner, Ralf Schlösser, Lutz G Schmidt, Andrea Schmitt, Markus Jäger, Gerd Buchkremer, Peter Falkai, Stefan Klingberg, Wolfgang Köpcke, Wolfgang Maier, Heinz Häfner, Christian Ohmann, Hans J Salize, Frank Schneider, Hans-Jürgen Mölle. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry. vol 68. issue 11. 2008-01-03. PMID:18052570. |
accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested. |
2008-01-03 |
2023-08-12 |
Not clear |
| Sahoo Saddichha, Narayana Manjunatha, Shahul Ameen, Sayeed Akhta. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. The Journal of clinical psychiatry. vol 68. issue 11. 2008-01-03. PMID:18052574. |
effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in india: a randomized, double-blind, controlled, prospective study. |
2008-01-03 |
2023-08-12 |
Not clear |
| Pavel Moh. Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuro endocrinology letters. vol 28 Suppl 1. 2007-12-27. PMID:17262004. |
the most investigated drugs that convincingly improve qol in schizophrenia are olanzapine and risperidone (including depot form). |
2007-12-27 |
2023-08-12 |
Not clear |
| Michael Riedel, Ilja Spellmann, Martin Strassnig, Anette Douhet, Sandra Dehning, Markus Opgen-Rhein, Rosamaria Valdevit, Rolf R Engel, Nikolaus Kleindienst, Norbert Müller, Hans-Jürgen Mölle. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European archives of psychiatry and clinical neuroscience. vol 257. issue 6. 2007-12-26. PMID:17629731. |
effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. |
2007-12-26 |
2023-08-12 |
Not clear |
| Michael Riedel, Ilja Spellmann, Martin Strassnig, Anette Douhet, Sandra Dehning, Markus Opgen-Rhein, Rosamaria Valdevit, Rolf R Engel, Nikolaus Kleindienst, Norbert Müller, Hans-Jürgen Mölle. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European archives of psychiatry and clinical neuroscience. vol 257. issue 6. 2007-12-26. PMID:17629731. |
in this study the effects of the atypical antipsychotics quetiapine and risperidone on cognitive function in patients with schizophrenia and with predominantly negative symptoms were compared. |
2007-12-26 |
2023-08-12 |
Not clear |
| Michael Riedel, Ilja Spellmann, Martin Strassnig, Anette Douhet, Sandra Dehning, Markus Opgen-Rhein, Rosamaria Valdevit, Rolf R Engel, Nikolaus Kleindienst, Norbert Müller, Hans-Jürgen Mölle. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European archives of psychiatry and clinical neuroscience. vol 257. issue 6. 2007-12-26. PMID:17629731. |
these results suggest that quetiapine and risperidone provide valuable treatment options for patients with schizophrenia with predominantly negative symptoms. |
2007-12-26 |
2023-08-12 |
Not clear |
| Dan Cohe. Effect of risperidone on ghrelin and glucose in schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 5. 2007-12-21. PMID:17875041. |
effect of risperidone on ghrelin and glucose in schizophrenia. |
2007-12-21 |
2023-08-12 |
Not clear |
| L Citrom. Paliperidone: quo vadis? International journal of clinical practice. vol 61. issue 4. 2007-12-20. PMID:17343660. |
paliperidone, the 9-hydroxy metabolite of risperidone, was approved on 20 december, 2006 by the us food and drug administration for the treatment of schizophrenia. |
2007-12-20 |
2023-08-12 |
Not clear |